Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Novel Genetic Structure Associated with an Extended-Spectrum β-Lactamase blaVEB Gene in a Providencia stuartii Clinical Isolate from Algeria

Daniel Aubert, Thierry Naas, Marie-Frédérique Lartigue, Patrice Nordmann
Daniel Aubert
Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, 94275 K.-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Naas
Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, 94275 K.-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Frédérique Lartigue
Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, 94275 K.-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Nordmann
Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, 94275 K.-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nordmann.patrice@bct.ap-hop-paris.fr
DOI: 10.1128/AAC.49.8.3590-3592.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A ceftazidime-resistant Providencia stuartii isolate from Algeria harbored a ca. 160-kb conjugative plasmid that contained a truncated blaVEB-1b gene flanked by three 135-bp repeated elements. This work gives further evidence of the worldwide spread of blaVEB genes that are associated with genetic structures other than class 1 integrons.

Providencia stuartii is frequently isolated from urinary tract infections of hospitalized patients (15). P. stuartii is naturally resistant to aminopenicillins and narrow-spectrum cephalosporins due to a chromosomally expressed Ambler class C cephalosporinase (AmpC) (1, 4). Resistance to expanded-spectrum cephalosporins in P. stuartii clinical isolates results mostly from overexpression of AmpC, but acquisition of extended spectrum β-lactamases (ESBL) such as TEM-, SHV-, or CTX-M-type enzymes have also been reported (3, 6, 19, 20).

The ESBL blaVEB-1 gene has been reported as part of class 1 integrons in several gram-negative rods from France (16), the Near East (Kuwait [18]), and Far East (Asia [5, 7, 8, 10, 11, 13, 17]). However, a novel genetic environment of a blaVEB-1a gene has been characterized in a Pseudomonas aeruginosa clinical isolate from India (2). This blaVEB-1a gene was chromosomally located, and, instead of being surrounded by a class 1 integron structure, it was flanked by two 135-bp sequences, named repeated elements (Re), that were bracketed themselves by two truncated 3′-conserved sequences (3′-CS) (9) of class 1 integrons in direct-repeat orientation (2). These Re carried a strong promoter that drove the expression of the downstream blaVEB-1a gene (2).

In the present work, a peculiar genetic environment of the blaVEB-1-like gene was characterized from a multidrug-resistant P. stuartii clinical isolate from a patient coming from Algeria.

Clinical P. stuartii isolate BI was recovered in 2004 from rectal and nasal swabs performed at admission at the Bicêtre Hospital of a 65-year-old patient that was directly transferred from a hospital located in Alger (Algeria). This patient suffered from septic shock with multiorgan failure. P. stuartii BI was identified by standard biochemical techniques (API-20E; bioMérieux, Marcy-l'Etoile, France).

A routine antibiogram, determined by disk diffusion method on Mueller-Hinton (MH) agar as previously described (17), revealed that P. stuartii BI was resistant to most β-lactams except imipenem and to chloramphenicol, fosfomycin, amikacin, gentamicin, kanamycin, netilmicin, tobramycin, streptomycin, tetracycline, and trimethoprim-sulfamethoxazole and was susceptible to ciprofloxacin, nalidixic acid, and rifampin. A synergy image between cefepime- and clavulanate-containing disks on MH agar plates suggested the presence of an ESBL (Fig. 1A). In addition, a marked synergy image between cefepime-, aztreonam-, and cefoxitin- or imipenem-containing disks suggested the presence of a VEB-type β-lactamase, since VEB-type enzymes have an unusual synergy pattern due to very low Km values for cefoxitin and imipenem (Fig. 1B) (13, 17).

Mating-out experiments, performed in liquid medium as previously described (17), between the P. stuartii BI isolate and a laboratory-obtained streptomycin- and rifampin-resistant Escherichia coli DH10B strain (Life Technologies, Eragny, France) yielded ticarcillin-resistant transconjugants at a frequency of ca. 2 × 10−4. The transconjugants had identical resistance profiles, and E. coli DH10B(pNat-BI) was retained for further analysis. Plasmid DNA extraction as previously described (17) identified a plasmid in P. stuartii BI and in E. coli DH10B (pNat-BI) of ca. 160 kb (data not shown).

This plasmid conferred resistance to amino-, carboxy-, and ureidopenicillins; to narrow- and expanded-spectrum cephalosporins; to aztreonam; and to chloramphenicol, gentamicin, kanamycin, tetracycline, and trimethoprim-sulfamethoxazole. MICs of β-lactams for P. stuartii BI and E. coli DH10B(pNat-BI), determined and interpreted as described previously (14, 17), mirrored the results obtained with disk diffusion susceptibility testing (Table 1). The resistance to β-lactams was partially reduced by tazobactam and clavulanic acid addition.

PCR amplification experiments using internal primers specific for blaTEM, blaSHV, blaPER-1, blaVEB-1, and blaGES-1 genes and whole-cell DNA of P. stuartii BI and E. coli DH10B(pNat-BI) as templates were as described previously (16). The blaTEM, blaSHV, and blaVEB-1 gene-specific primers yielded PCR products for P. stuartii BI and E. coli DH10B(pNat-BI). Sequencing of these PCR products revealed internal and partial sequences that were identical to those of the blaTEM-2, blaSHV-2, and blaVEB-1 genes. This result indicated that these β-lactamase genes were located on the same conjugative plasmid, thus further supporting previous findings that blaVEB-1-like genes are mostly plasmid located in Enterobacteriaceae, whereas they are chromosomally located in P. aeruginosa and Acinetobacter baumannii (7, 8, 16).

β-Lactamase extracts of cultures of P. stuartii BI and E. coli DH10B(pNat-BI) were prepared and subjected to analytical isoelectric focusing, as previously described (13). P. stuartii BI expressed four β-lactamases with pI values of 5.6, 7.4, 7.6, and 8.9, consistent with those of β-lactamases of TEM-2, VEB-1, SHV-2, and AmpC from P. stuartii, respectively (4, 13). The pI values of 5.6, 7.4, and 7.6 were also identified with culture extracts of E. coli DH10B(pNat-BI).

PCR amplification experiments failed using primers located in the blaVEB-1 gene and in the class 1 integron conserved sequences (5′-CS and 3′-CS [9]) or in genes known to be associated with the blaVEB-1 gene (e.g., aadB, cmlA5, and arr-2) (13), thus suggesting a different genetic environment.

To determine the surrounding sequences of the blaVEB-1-like gene in P. stuartii BI, PstI-restricted fragments of whole-cell DNA of P. stuartii BI were ligated into PstI-restricted vector pBBR1MCS.3 (12), followed by electroporation into E. coli DH10B. Recombinant clones were selected on ceftazidime (4 μg/ml)- and tetracycline (15 μg/ml)-containing plates. Recombinant plasmid pRec-BI, expressing the blaVEB-1-like gene, contained a 4.3-kb PstI insert. Sequencing of the entire blaVEB-1-like gene revealed 100% nucleotide identity with the blaVEB-1b gene reported previously in a P. aeruginosa isolate from Kuwait (18) that differed from the blaVEB-1 gene sequence (17) by two nucleotide substitutions that led to two amino acid changes (I18V and V19E) located in the leader peptide sequence.

Sequence analysis on both sides of the blaVEB-1b gene revealed genetic structures identical to those found in P. aeruginosa 10.2 from India (2) (Fig. 2A). Indeed, the blaVEB-1b gene cassette and qacEΔ1 from the upstream 3′-CS region were truncated since they were not preceded by their typical recombination core site sequence (Fig. 2B). The breakpoints were at the same location compared to P. aeruginosa 10.2 (Fig. 2A). However, instead of a 336-bp DNA stretch that was flanked by two Re1 sequences in P. aeruginosa 10.2, a single 135-bp Re1 DNA sequence was found in P. stuartii BI (Fig. 2B). The region located downstream of the blaVEB-1b gene in P. stuartii BI was identical to that of blaVEB-1a in P. aeruginosa 10.2, including the truncated tetracycline resistance gene (tetAΔ1), the two 135-bp DNA stretches in opposite orientations (Re2 and Re3), and, at the outermost right hand, part of a second 3′-CS region containing a sul1 gene (Fig. 2B). These Re (Re1, Re2, and Re3) were identical to those described in P. aeruginosa 10.2 (2).

This is the first report of a blaVEB-like gene from Africa, further illustrating the worldwide spread of VEB-type β-lactamases. Moreover, it is the first report of that ESBL in P. stuartii and the second report of blaVEB-like genes being flanked by Re. The function of these Re in gene mobilization will be further investigated. Finally, this report underlines that cassette-associated β-lactamase genes may be found on genetic structures that are different from typical class 1 integrons and that may contribute to their spread. The blaVEB-1 gene cassette is the first example of an ESBL gene associated with both integrons and Re sequences.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Double-disk synergy test with blaVEB-1-positive P. stuartii strain BI on MH agar plates with clavulanate (A) or imipenem and cefoxitin (B) as inhibitors. The disks tested contained ticarcillin plus clavulanate (TCC), imipenem (IMP), cefoxitin (FOX), cefepime (FEP), and aztreonam (AZT).

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

Schematic representations of the genetic environment of the blaVEB-1a gene in P. aeruginosa 10.2 (A) and of the blaVEB-1b in P. stuartii BI (B) (2). The breakpoints and the Re in the blaVEB-1-like gene environment are designated by broken lines and black triangles, respectively. The coding regions are shown as boxes, with an arrow indicating the orientation of transcription and white circles indicating the 59-bp element (59-be). Restriction sites that were used for cloning are indicated. Dashed lines in boldface indicate regions that were identified using PCR (the sequences of primers used are available upon request). The −10 and −35 promoter sequences of Re1 as well as the transcriptional initiation site (+1) are indicated by shaded boxes (2).

View this table:
  • View inline
  • View popup
TABLE 1.

MICs of β-lactams for the P. stuartii BI clinical isolate, E. coli DH10B harboring natural plasmid pNat-BI and recombinant plasmid pRec-BI, and E. coli DH10B reference strain

ACKNOWLEDGMENTS

This work was funded by a grant from the Ministère de la Recherche (grant UPRES-EA 3539), Université Paris XI, Paris, France, and the European Community (6th PCRD, LSHM-CT-2003-503-335).

FOOTNOTES

    • Received 18 February 2005.
    • Returned for modification 23 March 2005.
    • Accepted 18 April 2005.
  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Ambler, R. P., A. F. Coulson, J.-M. Frere, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J.276:269-270.
    OpenUrlFREE Full Text
  2. 2.↵
    Aubert, D., D. Girlich, T. Naas, S. Nagarajan, and P. Nordmann. 2004. Functional and structural characterization of the genetic environment of an extended spectrum β-lactamase blaVEB gene from a Pseudomonas aeruginosa isolate obtained in India. Antimicrob. Agents Chemother.48:3284-3290.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev.14:933-951.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother.39:1211-1233.
    OpenUrlFREE Full Text
  5. 5.↵
    Cao, V., T. Lambert, D. Q. Nhu, H. K. Loan, N. K. Hoang, G. Arlet, and P. Courvalin. 2002. Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob. Agents Chemother.46:3739-3743.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Franceschini, N., M. Perilli, and B. Segatore. 1998. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum β-lactamase, TEM-60. Antimicrob. Agents Chemother.42:1459-1462.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Girlich, D., T. Naas, A. Leelaporn, L. Poirel, M. Fennewald, and P. Nordmann. 2002. Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin. Infect. Dis.34:603-611.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Girlich, D., L. Poirel, A. Leelaporn, A. Karim, C. Tribuddharat, M. Fennewald, and P. Nordmann. 2001. Molecular epidemiology of the integron-located VEB-1 extended-spectrum β-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J. Clin. Microbiol.39:175-182.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Hall, R. M., and C. M. Collis. 1995. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. Mol. Microbiol.15:593-600.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Jiang, X., Y. Ni, Y. Jiang, F. Yuan, L. Han, M. Li, H. Liu, L. Yang, and Y. Lu. 2005. Outbreak of infection caused by Enterobacter cloacae producing the novel VEB-3 beta-lactamase in China. J. Clin. Microbiol.43:826-831.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Kim, J. Y., Y. J. Park, S. I. Kim, M. W. Kang, S. O. Lee, and K. Y. Lee. 2004. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital. J. Antimicrob. Chemother.54:1144-1147.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Kovach, M. E., R. W. Phillips, P. H. Elzer, R. M. Roop II, and K. M. Peterson. 1994. PBBR1MCS: a broad-host-range cloning vector. BioTechniques16:800-802.
    OpenUrlPubMedWeb of Science
  13. 13.↵
    Naas, T., F. Benaoudia, S. Massuard, and P. Nordmann. 2000. Integron-located VEB-1 extended-spectrum β-lactamase gene in a Proteus mirabilis clinical isolate from Vietnam. J. Antimicrob. Chemother.46:703-711.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    National Committee for Clinical Laboratory Standards. 2004. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  15. 15.↵
    O'Hara, C. M., F. Brenner, and M. Miller. 2000. Classification, identification, and clinical significance of Proteus,Providencia, and Morganella. Clin. Microbiol. Rev.13:534-546.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Poirel, L., O. Menuteau, N. Agoli, C. Cattoen, and P. Nordmann. 2003. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol.41:3542-3547.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Poirel, L., T. Naas, M. Guibert, E. B. Chaibi, R. Labia, and P. Nordmann. 1999. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob. Agents Chemother.43:573-581.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Poirel, L., V. O. Rotimi, E. M. Mokaddas, A. Karim, and P. Nordmann. 2001. VEB-1-like extended-spectrum beta-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg. Infect. Dis.7:468-470.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Quinteros, M., M. Radice, N. Gardella, M. M. Rodriguez, N. Costa, D. Korbenfeld, E. Couto, G. Gutkind, and the Microbiology Study Group. 2003. Extended-spectrum beta-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother.47:2864-2867.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Tumbarello, M., R. Citton, T. Spanu, M. Sanguinetti, L. Romano, G. Fadda, and R. Cauda. 2004. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J. Antimicrob. Chemother.53:277-282.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Novel Genetic Structure Associated with an Extended-Spectrum β-Lactamase blaVEB Gene in a Providencia stuartii Clinical Isolate from Algeria
Daniel Aubert, Thierry Naas, Marie-Frédérique Lartigue, Patrice Nordmann
Antimicrobial Agents and Chemotherapy Jul 2005, 49 (8) 3590-3592; DOI: 10.1128/AAC.49.8.3590-3592.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel Genetic Structure Associated with an Extended-Spectrum β-Lactamase blaVEB Gene in a Providencia stuartii Clinical Isolate from Algeria
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Novel Genetic Structure Associated with an Extended-Spectrum β-Lactamase blaVEB Gene in a Providencia stuartii Clinical Isolate from Algeria
Daniel Aubert, Thierry Naas, Marie-Frédérique Lartigue, Patrice Nordmann
Antimicrobial Agents and Chemotherapy Jul 2005, 49 (8) 3590-3592; DOI: 10.1128/AAC.49.8.3590-3592.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
ceftazidime
Enterobacteriaceae Infections
Providencia
beta-lactamases

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596